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The Luke (LKE) blood group antigen is a high-in-cidence RBC antigen expressed by the majority(99%) of blood donors.1-4 Like many blood groupantigens, LKE can vary in strength, with approxi-
mately 78 to 89 percent of donors typing as LKE-strong-
positive (LKE-str+) and 10 to 20 percent typing as LKE-
weak-positive (LKE-wk+). A LKE-negative (LKE-neg)
phenotype has also been described in 0.07 to 2 percent of
donors, probably as an autosomal recessive phenotype.1,5
It is interesting that p and Pk RBCs also type as LKE-neg,
which suggests a possible relationship between LKE and the
P blood group family.1-3,5 Even among P1 and P2 donors,
there is evidence of an interaction between LKE and P blood
group family antigens.3,5 In a family study including three
LKE-neg persons, Bruce et al.3 reported elevated Pk expres-
sion on LKE-neg RBCs. To date, alloantibodies against LKE
have been rare and clinically insignificant.1,3-6
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BACKGROUND:  Luke (LKE) is a high-frequency RBC
antigen, related to the P blood group system. A LKE-
negative phenotype is found in 1 to 2 percent of donors
and may be associated with increased Pk. Because Pk
and similar glycolipids are receptors for shiga toxin on
cell membranes, a LKE-negative phenotype could have
implications for infections by Shigella dysenteriae and
enterohemorrhagic Escherichia coli.
STUDY DESIGN AND METHODS:  Volunteer donors (n
= 257) were serologically typed for LKE with a LKE
MoAb, MC813-70. LKE-strong-positive, LKE-weak-posi-
tive and LKE-negative RBCs were analyzed for Pk, P,
LKE, and shiga toxin binding by immunofluorescence
flow cytometry, high-performance thin-layer chromatog-
raphy, scanning densitometry, and high-performance
thin-layer chromatography immunostaining.
RESULTS:  Among Iowa donors, 78.6 percent were LKE-
strong-positive, 20.2 percent were LKE-weak-positive,
and 1.2 percent were LKE-negative. There was an in-
verse expression of Pk and LKE on RBCs. Pk expression
was increased on LKE-negative RBCs and was associ-
ated with increased shiga toxin binding. A LKE-active
glycolipid was identified in the ganglioside fraction of
LKE-strong-positive RBCs.
CONCLUSION:  A LKE-negative phenotype is associ-
ated with increased expression of Pk on RBCs. Differ-
ences in Pk and LKE expression may play a role in host
susceptibility to infection with S. dysenteriae and E. coli.
ABBREVIATIONS: C-M = chloroform-methanol; C-M-W = C-M-
water; DPA = diphenylamine; GSL(s) = glycosphingolipid(s);
HPTLC = high-performance thin-layer chromatography; HUS =
hemolytic uremic syndrome; LKE-neg = Luke-negative; LKE-str+
= Luke-strong-positive; LKE-wk+ = Luke-weak-positive; MCFI =
MCF intensity; MSGG = monosialo-galactosyl-globoside; SSEA =
stage-specific embryonic antigen; ST = shiga toxin; STEC = ST-
producing E. coli.
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LKE has not yet been isolated from RBCs; however,
there is evidence indicating that LKE is a monosialo-galac-
tosyl-globoside (MSGG). Originally isolated from a terato-
carcinoma cell line,7 MSGG is a sialic acid-containing
glycosphingolipid (GSL) or ganglioside, biosynthetically
related to the P blood group system.8 MSGG expression is
dependent on prior synthesis and subsequent elongation
of Pk and P antigens.9 Like LKE, MSGG is not expressed on
the RBCs of p and Pk persons, which are unable to synthe-
size Pk and P, respectively.6,8 Furthermore, MoAbs to MSGG
have anti-LKE activity in hemagglutination studies.2 In ad-
dition to teratocarcinoma cells, MSGG has been identified
on human endothelium, smooth muscle,10 dorsal horn,11
and kidney cells, and platelets.12-14
Clinically, LKE may play a role in embryonic develop-
ment and infection. In mice, LKE is a stage-specific embry-
onic antigen (SSEA) on oocytes, early-cleavage-stage em-
bryos, and midgestation embryos, where LKE is a marker
of extraembryonic visceral endoderm and visceral yolk sac
cells.15,16 LKE is also a receptor for P-fimbria, a bacterial
adhesin expressed by uropathogenic Escherichia coli
strains, which facilitates E. coli colonization and infection
of vaginal and uroepithelium.12 LKE could also play an in-
direct role in infectious diarrhea, hemorrhagic colitis, and
hemolytic uremic syndrome (HUS), because of infections
with Shigella dysenteriae and shiga toxin-producing E. coli
(STEC).17 A ricin-like cytotoxin, shiga toxin (ST) binds to
renal endothelium and tubular epithelium via recognition
of Pk on cell membranes.17-19 Increases in Pk expression, by
either enzymatic modification of cell membranes or stimu-
lation of Pk synthesis by inflammatory cytokines, are ac-
companied by parallel increases in ST binding and cytotox-
icity.18,20,21 Likewise, elevated Pk expression associated with
an LKE-neg phenotype could potentially increase host sus-
ceptibility to ST through increased binding of toxin to tar-
get cell membranes.22
In this study, we initially examined the prevalence of LKE
phenotypes in a Midwest donor population. The relationship
between LKE and P blood group system antigens and the
biochemical basis of the relationship were examined by flow
cytometry and high-performance thin-layer chromatogra-
phy (HPTLC) of isolated RBC GSLs. In addition, we exam-




RBC samples were collected in EDTA from volunteer blood
donors in accordance with the human investigation review
committee at one of our institutions (DeGowin Blood Cen-
ter, University of Iowa). For most experiments, RBCs were
enzymatically modified as described.1,2 Briefly, 1 drop of
packed, washed RBCs was incubated with 4 drops of diluted
papain (EC 3.4.22.2, Sigma Chemical Co., St. Louis, MO; 3.3
units/mL final in 0.067 M phosphate buffer, pH 7.7) at 37°C
for 15 minutes. In selected donors, separate aliquots of
washed RBCs were digested with neuraminidase in paral-
lel (EC 3.2.1.18, from Clostridium perfringens, 0.2 units/mL
in PBS-1% BSA; Sigma) as described.2 After incubation, cells
were washed three times in normal saline and then resus-
pended as a 1-percent RBC suspension in cold Alsever’s
solution with 12-percent BSA for serologic typing or as a 3-
percent RBC suspension in PBS with 1-percent BSA for flow
cytometry.
Immunologic reagents
MoAbs against P antigen (MoAb MC631, mouse IgM), LKE
(MoAb MC813-70, mouse IgG), and Lewisx antigen (MoAb
MC480, anti-CD15; mouse IgM) were purchased as hybri-
doma supernatants (MoAbs MC631 and MC480) or purified
mouse ascites (MoAb MC813-70) from the Developmental
Studies Hybridoma Bank maintained by the Department of
Biology (contract NO1-HD-2-3144, University of Iowa, Iowa
City, IA).7,23,24 MoAbs Pk002 (anti-Pk, -P1) and P2 (anti-CD62,
mouse IgG) were purchased from Accurate Chemical (San
Diego, CA).25 ST (holotoxin, B subunits) and rabbit
polyclonal anti-ST were a gift of Arthur Donohue-Rolfe, MD
(Tufts University, Boston, MA). Anti-A, anti-B, and anti-P1
were purchased from Gamma Biologicals (Houston, TX).
For flow cytometry, isolated ST B subunits were labeled with
FITC (isomer I; Sigma) as described.22,26 Polyclonal anti-
mouse IgG and FITC-labeled anti-mouse immunoglobulins
(IgG and IgM) were purchased (Sigma). Biotinylated anti-
rabbit IgG, anti-mouse IgG, anti-mouse IgM, avidin-linked
alkaline phosphatase (ABC kit), and alkaline phosphatase
substrate (SK-5200) were also purchased (Vector Laborato-
ries, Burlingame, CA).
Serologic tests
All donors were typed for ABO and Rh at the DeGowin Blood
Center. Selected donors were also typed for P1 with a hu-
man polyclonal anti-P1. ABO, Rh, and P1 typing were per-
formed as described according to manufacturers’ instruc-
tions.
All donors were typed for LKE antigen as described, with
modification.2 Briefly, 1 drop of a 1-percent papainized RBC
suspension in Alsever’s solution with 12-percent BSA and 1
drop of a murine monoclonal anti-LKE (MoAb MC813-70,
concentrated mouse ascites diluted 1-in-100 in PBS-6% BSA)
were incubated for 20 minutes at 4°C and then centrifuged
(3400 rpm, 25 sec). Samples that showed macroscopic ag-
glutination after 20-minute incubation were typed as LKE-
str+. Donor samples giving weak or negative reactions were
washed and then incubated with a poly-clonal mouse IgG
(50 µg/mL in PBS-1% BSA; Sigma) for 10 minutes at 4°C and
then centrifuged. Donor samples that agglutinated in the
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antiglobulin phase were typed as LKE-wk+. Donor samples
that failed to agglutinate were typed as LKE-neg.
To exclude the possibility that weak or absent hemag-
glutination was the result of insufficient papain digestion,
all LKE-wk+ and LKE-neg samples were typed for P, a high-
incidence, cryptic RBC GSL antigen.27 For P typing, 1 drop
of a 1-percent papainized RBC suspension and 1 drop of
MoAb MC631 supernatant (neat) were incubated for 20
minutes at 4°C.2,7,23 Cells were then centrifuged and the re-
sults read macroscopically (3-4+ agglutination). For both
LKE and P typing, all solutions were stored and used at 4°C.
Flow cytometry
Flow cytometry was performed on untreated, neuramini-
dase-treated, and papainized RBCs from 13 donors. For
MoAb staining, 25 µL of a 3-percent RBC suspension was
incubated with MoAb diluted in PBS with 1-percent BSA
(100 µL final vol) for 30 minutes at 4°C. Cells were washed
twice with PBS with 1-percent BSA and then labeled with
an FITC-labeled anti-mouse immunoglobulin (IgG or IgM)
for 30 minutes at 4°C. To label RBCs with ST, 25 µL of 3-per-
cent RBC suspension, 20 µL of FITC-labeled ST (100 µg/mL
stock, 2 µg/sample total), and 55 µL of PBS with 1-percent
BSA buffer were incubated for 2 hours at 4°C. After stain-
ing, cells were washed again and then resuspended in PBS
with 1-percent paraformaldehyde (400 µL final vol). Con-
trols included P2 MoAb (IgG isotype), MC480 MoAb (IgM
isotype), and ST-free, FITC dialysate filtrate.22
Samples were analyzed on a flow cytometer (440,
Becton Dickinson, Brea, CA) equipped with an argon laser.
FACS data were collected on a computer equipped with
software (DESK; Wayne Moore, Stanford University, Palo
Alto, CA). Cells were gated on forward and orthagonal scat-
ter with a minimum of 10,000 events measured per sample.
All samples were performed in duplicate and the results
recorded as the percentage of FITC-positive RBCs and log
MCF intensity (MCFI). Final graphic output was performed
using canvas software (Macintosh, Apple, Cupertino, CA).
GSL isolation
GSLs were isolated from individual RBC samples (approx.
1 mL packed RBCs) as described by Ledeen and Yu28 with
modification.22 Briefly, RBCs were extracted with 20 mL of
chloroform-methanol (C-M) 1:1 (vol/vol) for 72 hours. The
total lipid extract was dried, resuspended in 200 mL of C-
M-water (C-M-W) 30:60:8 (vol/vol) and applied to an an-
ion exchange column (DEAE, A25, Sigma; 10-mL bed vol).
Neutral lipids were isolated by washing the column with 200
mL of C-M-W 30:60:8 (vol/vol). The column was then
stripped of acidic lipids with 150 mL of C-M with 0.8M so-
dium acetate 30:60:8 (vol/vol). The neutral and acidic lipid
fractions were dried in vacuo, suspended in methanolic
NaOH (0.1N-0.3N, 2 hours, 37°C), dried, and then dialyzed
against distilled water (MW cutoff, 14000; Spectra-Por,
Houston, TX). For neutral lipids, the dried dialysis residue
was resuspended in 50 mL of chloroform and applied to a
silicic acid column (10-mL bed vol, 40 µm; J.T. Baker,
Phillipsburg, NJ). The column was sequentially washed with
an additional 100 mL of chloroform and 50 mL of ethyl ac-
etate and then stripped of neutral GSL with 50 mL each of
acetone-methanol 9:1 and 7:3 (vol/vol). The last two frac-
tions were pooled as the total neutral GSL fraction and
dried. For acidic lipids, the dried dialysis residue was resus-
pended in 30 mL of C-M 85:15 (vol/vol), applied to a silicic
acid column (10 mL, 40 µm), and then washed with 170 mL
of C-M 85:15 (vol/vol) to remove sulfatides. Gangliosides
were isolated by stripping the column with 130 mL of C-M
1:2 (vol/vol).
HPTLC
HPTLC was performed according to published procedures
using glass or aluminum-backed HPTLC plates (Merck,
Darmstadt, Germany).29 GSLs were blotted onto HPTLC
plates and then developed in a solvent of C-M-W 65:25:4
(vol/vol). For neutral RBC GSLs, dried samples were resus-
pended in 100 µL of C-M 1:1 (vol/vol), and 5 µL was applied
on each HPTLC lane. Because RBCs express little ganglio-
side (0.7 µg lipid-bound sialic acid/mL RBC),28,30 RBC gan-
gliosides were diluted in 25 µL of C-M 1:1 and the entire
sample was blotted. GSL controls included isolated
glucosylceramide (CMH, Table 1), lactosylceramide (CDH),
globotriaosylceramide (Gb3 or P
k), globoside (Gb4, P; Sigma;
5 µg/lane), and total kidney ganglioside (40 µg/lane). GSLs
were detected by spraying with either diphenylamine (DPA)
reagent (Sigma) or by immunostaining as described below.
GSL bands were characterized by intensity (% total stain-
ing density) and relative mobility (Rf) by scanning densito-
metry at 370 nm (Shimadzu Instruments, Columbia,
MD).28,29 Error in mobility measurements (Rf ± SD) was less
than 0.01 unless otherwise stated. For relative expression
of individual GSL bands, GSL samples were examined in
triplicate and reported as the adjusted percentage of total
RBC-neutral GSL. The latter was obtained by subtracting
the area (mm2) of minor RBC GSLs (<15%) from the total
DPA positivity.
HPTLC immunostaining
HPTLC immunostaining was performed as described by
Magnani et al.31 and modified by Buehler and Macher.32
Briefly, air-dried, solvent-developed plates were dipped in
a hexane solution of 0.4-percent poly(iso-butyl)metha-
crylate (Polysciences, Warrington, PA) for 60 seconds and
then air-dried again. The plates were blocked with Tris
buffer (40 mM Tris-HCl, 150 mM NaCl, 1% BSA, 0.1% so-
dium azide; pH 7.8) for 45 minutes and then overlaid with
primary antibody diluted in Tris buffer for 1 hour. Plates
were gently washed with PBS, incubated with a biotinylated
anti-mouse Ig antibody (1 hour), washed, and then allowed
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to bond with an avidin-linked alkaline phosphatase for 30
minutes. Bound antibody was detected by overlying plates
with an alkaline phosphatase substrate in cold (4°C) 100 mM
Tris-HCl, pH 9.5. Overlays with ST were performed as de-
scribed, using ST holotoxin (final concentration, 50 ng/mL;
2-hour incubation), rabbit ST polyclonal antibody (final con-
centration, 1:5000 in PBS-1% BSA), and biotinylated anti-rab-
bit IgG (Vector). A toxin-free, buffer control was run in par-
allel.22
Statistics
GSL expression was compared by using a two-tailed t test
and the Mann-Whitney U test. A p value <0.05 was consid-
ered significant.33 Graphics and statistical correlation be-
tween flow cytometry and HPTLC data was obtained by
using software (Cricketgraph, Apple) for the Macintosh.
RESULTS
Distribution of Luke phenotypes among Iowa blood
donors
A total of 257 volunteer whole-blood donors were serologi-
cally typed for LKE antigen by use of the LKE MoAb, MC813-
70.2,4 Because the LKE-neg phenotype is reportedly higher
among group A and P1 phenotypes,
1 all LKE-wk+ and LKE-
neg samples were serologically typed for ABO and P1 anti-
gens. As shown in Table 2, 254 (98.8%) of 257 Iowa donors
typed as LKE-positive. Among LKE-positive donors, 78.6
percent typed as LKE-str+, 20.2 percent as LKE-wk+, and 1.2
percent as LKE-neg. In contrast to early reports,1 there was
no association between either a group A or P2 phenotype
and a LKE-wk+ and LKE-neg phenotype (data not shown).
In general, the distribution of LKE phenotypes among Iowa
donors was comparable to that reported among Northern
European donors (Table 2).1-4
LKE-negative donors express LKE antigen
The presence of LKE was also examined by one-color im-
munofluorescence flow cytometry. Papainized RBCs from
13 donors (3 LKE-neg, 2 LKE-wk+, and 8 LKE-str+) were
incubated with MoAb MC813-70, followed by an FITC-la-
beled anti-mouse immunoglobulin secondary antibody. As
an internal positive control, RBCs were also stained for the
presence of P antigen with MoAb MC631. To correct for
nonspecific binding, RBCs were incubated with mouse
monoclonal IgG (P2 MoAb, anti-CD62) and IgM (MoAb
MC480, anti-Lewisx) isotype controls. Results were reported
as the percentage of FITC-positive cells and MCFI.
As shown in Table 3, nearly 100 percent of LKE-str+ and
LKE-wk+ RBCs were MoAb MC813-70-positive. As reported






Globotetraosylceramide (Gb4, P, globoside) GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1´Cer
IV3-β-Gal-globotetraosylceramide (Gal-Gb4, SSEA-3) Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1´Cer
IV3-β-Galα1-4Gal-globotetraosylceramide (band 0.03) Galα1→4Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1´Cer
IV3-β-Fucα1-2Gal-globotetraosylceramide (globo-H) Fucα1→2Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1´Cer





* GSL structures and trivial names as recommended by the International Union of Pure and Applied Chemistry–International Union of Biology
Commission on Biochemical Nomenclature.9
TABLE 2. Distribution of LKE phenotypes among volunteer blood donors
Glasgow/
LKE Iowa*† London1‡ London2† Western Scotland3†‡ Netherlands4†
phenotype Number (%) Number (%) Number (%) Number (%) Number (%)
Positive 254 (98.8) 445 (98.0) 503 (99.0) 2396 (99.8) 891 (99.3)
LKE-str+ 202 (78.6) 380 (83.7) 453 (89.2) NA NA 706 (78.7)
LKE-wk+ 052 (20.2) 065 (14.3) 050 0(9.8) NA NA 185 (20.6)
Negative
LKE-neg 003 0(1.2) 009 0(2.0) 005 0(1.0) 0004 00(0.17) 006 0(0.7)
    Total 257 (100)00. 454 (100).00 508 (100).00 2400 (100).00 897 (100).00
* This study.
† Donors typed with MoAb MC813-70.
‡ Donors typed with human polyclonal anti-LKE.
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by Tippet et al.,2 weak MoAb MC813-70 staining was also
observed with LKE-neg RBCs. A comparison of LKE pheno-
type and MCFI showed a good correlation, with a progres-
sive decrease in MoAb MC813-70 MCFI with a LKE-str+,
LKE-wk+, and LKE-neg phenotype, respectively (Table 3).
In contrast, there was no significant difference in P expres-
sion (MoAb MC631) among the three LKE phenotypes.
LKE is sensitive to neuraminidase
Neuraminidase is reported to inhibit MoAb MC813-70 bind-
ing to RBCs by removing a terminal sialic acid necessary for
MoAb MC813-70 recognition (Table 1).2,7 To confirm the sensi-
tivity of LKE to neuraminidase, MoAb MC813-70 binding to
untreated, papain-treated, and neuraminidase-treated RBCs
was compared by flow cytometry. As before, MoAb MC631
was included as a control: Unlike LKE, P is a nonsialylated
or “neutral” GSL and, therefore, insensitive to neuraminidase.
As shown in Fig. 1, MoAb MC813-70 binding was ob-
served to papain (heavy solid line) and neuraminidase-
treated (hatched line) RBCs; however, the percentage of
positive cells and MCFI were relatively decreased in
neuraminidase-treated RBCs. This was particularly striking
with LKE-neg RBCs, in which neuraminidase treatment
resulted in a 44.8-percent decrease in the percentage of
FITC-positive cells and a 17.2-percent decrease in MCFI. In
contrast, neuraminidase treatment increased MoAb MC631
binding, as determined by the MCFI, in most samples. The
observed increase in MoAb MC631 binding is consistent
with the conversion of LKE to Gal-Gb4 (Table 1), which is
strongly recognized by MoAb MC631.7,23 It is notable that
no MoAb MC813-70 binding was observed in the absence of
enzyme modification (thin line).
ST binding is related to donor LKE phenotype
In a family study of several LKE-neg donors, Bruce et al.3
reported an apparent association between LKE phenotype
and Pk expression. Specifically, LKE-neg RBCs appeared to
express significantly higher Pk, as determined by agglutina-
tion with a polyclonal anti-Pk. To determine if elevated Pk
is a common finding on LKE-neg RBCs, we compared Pk and
LKE expression on RBCs by flow cytometry. To detect Pk,
RBCs were stained with FITC-labeled ST B subunits, which
bind Pk and P1 via a terminal Galα1-4Gal-R epitope.
17,22
In agreement with Bruce et al.,3 there was a noticeable
increase in ST binding to LKE-neg RBCs (Table 3).5 Further-
more, there was an inverse relationship between LKE and
Pk antigen expression. As shown in Fig. 2, a direct compari-
son of the fluorescence spectra by LKE phenotype shows a
progressive decrease in ST MCFI with increasing MoAb
MC813-70 fluorescence. We also attempted to examine Pk
expression on RBCs with an anti-Pk MoAb, Pk002.24 Despite
multiple attempts, we were unable to demonstrate any
binding by MoAb Pk002 to intact RBC membranes.
Analysis of RBC GSLs
Both hemagglutination and immunofluorescence studies
suggested an increase in Pk expression on LKE-neg RBCs.
TABLE 3. P k, P, and LKE expression on RBCs by flow cytometry, LKE phenotype, and enzyme treatment
Donor LKE Enzyme MoAb MC18-70† MoAb MC631† ST†
phenotype treatment* Percentage positive MCFI Percentage positive MCFI Percentage positive MCN
LKE-str+ Untreated 1.2 ± 0.1 30.9 ± 1.0 79.2 ± 4.8 54.8 ± 11.6 58.0 ± 14.3 46.5 ± 8.8
Papain 93.7 ± 2.50 113.8 ± 1.10 073.4 ± 10.6 88.1 ± 9.80 57.3 ± 13.4 46.2 ± 7.2
Neuraminidase 91.5 ± 2.40 110.3 ± 2.40 79.4 ± 9.9 112.8 ± 10.20 NT NT
LKE-wk+ Untreated 1.2 ± 0.1 31.4 ± 1.0 70.2 ± 2.8 78.1 ± 1.1 0 83.6 ± 1.30 62.4 ± 1.0
Papain 95.5 ± 1.50 93.1 ± 3.6 80.3 ± 7.4 96.4 ± 12.4 83.7 ± 1.0 0 61.6 ± 1.2
Neuraminidase 89.9 ± 3.40 87.2 ± 5.0 88.9 ± 3.0 115.7 ± 5.300 NT NT
LKE-neg Untreated 1.0 ± 0.1 30.5 ± 1.0 037.0 ± 18.3 54.8 ± 11.6 98.8 ± 1.30 90.2 ± 7.7
Papain 61.0 ± 18.3 73.9 ± 3.0 070.9 ± 10.2 85.8 ± 9.70 98.9 ± 1.10 86.4 ± 6.7
Neuraminidase 33.0 ± 14.8 53.7 ± 7.4 77.6 ± 6.4 94.9 ± 10.4 NT NT
Control‡ Untreated 3.2 35.0 2.6 35 1.7 17
* Untreated, papain-modified, or neuraminidase-modified RBCs.
† Flow cytometry results reported as the mean ± SD of both the percentage of positive cells and the MCFI.
‡ ST, IgM, and IgG isotype controls as described in Materials and Methods (n = 2).
Fig. 1. LKE antigen is sensitive to neuraminidase. Untreated
(thin line), papain-modified (bold line), and neuraminidase-
modified (hatched line) RBCs were stained with MoAb MC813-
70 (anti-LKE, Panels A-C) or MoAb MC631 (anti-P, Panels D-
F). Samples shown include LKE-neg (A and D), LKE-wk+ (B
and E), and LKE-str+ (C and F) RBCs.
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cantly related where the (log) ST MCFI = 10.2 + %Gb3, R
2 =
0.93 (Fig. 5).
LKE-positive RBCs express a glycolipid with LKE
activity
It has been hypothesized that LKE on RBCs is a ganglioside.2
To determine whether RBCs express a sialylated glycolipid
with LKE activity, the entire ganglioside fraction from 1 mL
of packed RBCs was immunostained with MoAb MC813-70.
Human kidney ganglioside was included as a positive con-
trol. As shown in Fig. 6, a LKE-str+ band (Rf 0.01) was ob-
served in 4 of 4 LKE-str+ RBCs (Lanes 6-11). In LKE-neg and
LKE-wk+ samples, the concentration of LKE per mL of RBCs
was below the threshold for detection by HPTLC.31,32
These findings may suggest either an absolute increase in Pk
content, decreased crypticity of Pk on RBC membranes, or
synthesis of a novel Pk-like antigen on LKE-neg RBCs.3,5,34 To
investigate the basis underlying Pk expression on LKE-neg
RBCs, the RBC-neutral GSL fractions from 11 donors, rep-
resenting all three phenotypes, were isolated and examined
by HPTLC. GSLs were visualized and identified by chemical
staining with diphenylamine reagent (DPA) and HPTLC
immunostaining relative to known standards. Confirmation
of Pk antigen (Gb3, Table 1) was performed by HPTLC
immunostaining with ST and MoAb Pk002 as described.22
Differences in GSL expression were quantitated by scanning
densitometry of DPA-stained HPTLC plates and reported as
the adjusted percentage of total neutral GSL.
As reported by others (Fig. 3),35 the major neutral GSLs
of human RBCs were monoglycosylceramides to tetra-
osylceramides, which accounted for >85 percent of the total
RBC-neutral GSL. From the literature, mobility, and reactiv-
ity with GSL-specific MoAbs, the four major neutral GSLs
were identified as glucosylceramide (CMH, relative mobility
[Rf] 0.59; Table 1), lactosylceramide (CDH, Rf 0.40),
globotriaosylceramide (Gb3, Rf 0.25), and globoside (Gb4, Rf
0.16). As shown in Fig. 4, Gb3 (P
k) was confirmed by HPTLC
immunostaining with both ST and MoAb Pk002. ST and MoAb
Pk002 also recognized a second, faint GSL band (Rf 0.06),
which was identified as P1 (data not shown).
22 The identifica-
tion of both Gb3 and Gb4 in Samples 1 through 3 (LKE-neg)
excluded the possibility of a LKE-neg phenotype arising from
a rare p or Pk background (Fig. 4, Table 4).1,2,6,8
On scanning densitometry, significant differences were
noted in the relative expression of Gb3 (% total GSL). Specifi-
cally, the percentage of Gb3 in LKE-neg RBCs was nearly twice
that in LKE-pos RBCs (Table 4, Fig. 3). Increased Gb3 was
accompanied by significant increases in
the Gb3:CDH and Gb3:Gb4 ratios, which
suggest an increase in Gb3 and/or a de-
crease in Gb4 synthesis.
35,36 Although sta-
tistically insignificant, because of the small
number of samples examined, the per-
centage of Gb3 and the Gb3:CDH ratio
were also increased in LKE-wk+ RBCs.
Overall, there was a good correlation be-
tween HPTLC and flow cytometry data,
with both methods showing increased Pk
on LKE-neg and, possibly, LKE-wk+ RBCs.
Binding of ST to RBCs is related
to the percentage of Gb 3
To determine the relationship between
the percentage of Gb3 and the expression
of Pk on RBC membranes, ST MCFI was
plotted against Gb3 (% total RBC neutral
GSL; Table 4). As expected, the percent-
age of Gb3 and the ST MCFI were signifi-
Fig. 2. Inverse expression of Pk and LKE on RBCs. Papain-
modified RBCs from a LKE-neg donor (bold line), a LKE-wk+
donor (hatched line), and a LKE-str+ donor (dotted line)
stained with MoAb MC813-70 (Panel A) or ST (Panel B). Nega-
tive controls (thin line) included P2 MoAb (IgG, Panel A) and
ST-free, dialysate control (Panel B).
Fig. 3. Neutral GSL expression on RBCs by LKE phenotype. The total RBC-neutral GSL
fractions from a LKE-str+ donor (Panel A), a LKE-wk+ donor (Panel B), and a LKE-neg
donor (Panel C) were separated by HPTLC, chemically stained with DPA, and then
subjected to scanning densitometry: The numbers refer to the relative mobility (Rf) of
the major RBC GSL bands (Table 1); glucosylceramide (CMH, Rf 0.59), lactosylcera-
mide (CDH, Rf 0.40), globotriaosylceramide (Gb3, P
k; Rf 0.25), and globotetraosylcer-
amide (Gb4, P; Rf 0.16). OR, lane origin. Solvent was C-M-W 65:25:4 (vol/vol).
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DISCUSSION
The LKE blood group is a high-frequency RBC antigen among
Iowa donors. Overall, nearly 99 percent of Iowa donors were
identified as serologically positive for LKE by the LKE MoAb,
MC813-70. That is slightly more than the 98 percent reported
with human polyclonal anti-LKE, which suggests that MoAb
MC813-70 is more sensitive than polyclonal anti-LKE.1,2
Among Iowa donors, the distribution of LKE-str+ and LKE-
wk+ phenotypes is very similar to that reported for donors
in the Netherlands (Table 2).4 In contrast, the incidence of
LKE-neg is twice that among Danish donors, but very simi-
lar to the rate in British donors.1-4 Overall, the similarity
among Iowa and European blood donors in the distribution
of LKE phenotypes is not surprising, given the predominantly
white, European ancestry of most Iowa donors.
We also examined the expression of LKE on RBCs by
flow cytometry. With the exception of LKE-neg RBCs, there
was a good correlation between serologic phenotype and
immunofluorescence (MCFI). The weak MoAb MC813-70
positivity observed with LKE-neg RBCs may reflect the greater
sensitivity of flow cytometry in comparison to hemaggluti-
nation methods.37 Despite the latter, we observed no MoAb
MC813-70 binding to any RBC tested, regardless of LKE phe-
notype, in the absence of enzyme modification (Fig. 1). The
absence of MoAb MC813-70 binding to native, untreated
RBCs underscores the cryptic nature of LKE on RBC mem-
branes.1 A common finding among GSL antigens,27,38 the
crypticity of LKE on RBC membranes may reflect the small
numbers of antigens and masking by protein glycoconjugates.
We also screened RBCs for the presence of a LKE-active
glycolipid by HPTLC immunostaining. To date, it has been
hypothesized that LKE is an RBC ganglioside. This hypoth-
esis is based on the LKE-like activity of MoAb MC813-70,
which recognizes the globo-ganglioside MSGG (Table 1).2,7
Originally isolated from human teratocarcinoma, MSGG has
been identified in the ganglioside fraction of several human
tissues including human kidney,13 endothelium,10 and plate-
lets.14 In addition, human RBCs reportedly express one and,
possibly two disialo-globo-gangliosides related to MSGG
(DSGG and DG-4; Table 1).39,40 Although preliminary, a LKE-
active glycolipid was identified in the ganglioside fraction of
all four LKE-str+ RBC samples tested. Unfortunately, the
amount of RBC ganglioside available from our individual
donor samples (1 mL packed RBCs) was insufficient to per-
mit additional studies to elucidate
the structure of the LKE-active gly-
colipid identified. We have subse-
quently performed large-scale iso-
lation of RBC gangliosides to
characterize the structure of this
LKE-active glycolipid, as well as two
additional globo-gangliosides.41 The
results will be published in a subse-
quent report.
Clinically, the density or relative
expression of LKE on RBCs varies
among individuals, and it gives rise
to three serologic phenotypes—
LKE-str+, LKE-wk+, and LKE-neg.
In all populations studied to date,
the vast majority of donors (98-
99%) are LKE-positive, with only 1
to 2 percent typing as LKE-neg. In
fact, a LKE-positive phenotype is
more frequent than reported, as
Fig. 4. Confirmation of Gb3 in RBCs. To confirm that DPA Band
0.25 (Panel A) was Gb3, the RBC-neutral GSL fraction was
immunostained with ST (Panel B) and Pk002 MoAb (Panel C).
Lane numbers refer to Donors 1-11 (Table 4). Lane S is a Gb3
standard.
TABLE 4. RBC GSL distribution by LKE phenotype
RBC phenotype* Adjusted percentage of total RBC-neutral GSLs† Ratio area (mm2)‡
Donor‡ ABO/Rh P1 LKE‡ CMH CDH Gb3 (P
k) Gb4 (P) Gb3/CDH Gb3/Gb4
01 A+ + neg 3.3 12.0 26.9 57.8 2.2 0.46
02 O+ + neg 0.8 12.6 37.6 49.0 3.0 0.77
03 B+ + neg 4.1 11.2 31.9 54.2 3.5 0.56
04 O+ + wk+ 3.3 17.9 17.3 61.5 0.9 0.28
05 A+ + wk+ 1.7 20.1 21.7 56.5 1.1 0.38
06 O+ + str+ 2.8 14.5 16.0 66.7 1.1 0.24
07 A+ + str+ 2.5 11.4 16.1 70.0 1.4 0.23
08 O+ + str+ 1.0 19.4 17.0 62.6 0.90 0.27
09 A+ + str+ 2.2 19.1 17.7 61.0 0.90 0.29
10 O+ + str+ 6.6 19.7 17.7 56.0 0.9 0.35
11 O+ + str+ 1.0 12.6 19.1 67.3 1.5 0.28
Mean ± SD
LKE-negative (n = 3) 2.9 ± 1.7 11.2 ± 1.9 31.9 ± 5.4 54.2 ± 4.0 2.9 ± 0.65 0.60 ± 0.16
LKE-positive (n = 8)§ 2.6 ± 1.8 16.8 ± 3.5 17.8 ± 1.8 62.7 ± 5.0 1.1 ± 0.24 0.29 ± 0.05
p value|| >0.50 0<0.02 00<0.001 0<0.02 0.<0.001 <0.001
* RBC phenotype by serologic test.
† Relative distribution of CMH, CDH, Gb3, and Gb4 as determined by scanning densitometry of
DPA-stained HPTLC plates. The percentages were normalized to equal 100 percent.
‡ Ratio of area (mm2) as determined by densitometry of DPA-stained HPTLC plates.
§ LKE-str+ and LKE-wk+.
|| Two-tailed t test.
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ever, the study was confined to a single kindred containing
multiple LKE-neg donors and, therefore, may not be appli-
cable to all LKE-neg RBCs. In addition, the results were based
on hemagglutination scores using a human polyclonal anti-
Pk, which suggests either an increase in total Pk, altered ex-
posure of Pk, or cross-reactivity with a novel, Pk-like GSL
related to LKE. The latter was hypothesized to reflect replace-
ment of the terminal sialic acid of MSGG with an αGal, giv-
ing rise to a Galα1-4Gal-Gb4 structure with P
k-like activity
(Band 0.03, Table 1).5,22,34
As a consequence, we compared LKE and Pk antigen
expression on RBCs of different LKE phenotypes by both flow
cytometry and HPTLC. As reported by Bruce et al.,3 all three
LKE-neg donors showed increased Pk expression by flow
cytometry and HPTLC. Because the three donors were un-
related, these results suggest that increased Pk is a common
feature of LKE-neg RBCs.5 Furthermore, there was an in-
verse relationship between Pk and LKE expression, with the
weakest Pk expression observed on LKE-str+ RBCs (Fig. 2,
Table 3). Elevated Pk on LKE-neg RBCs was due to increased
total Pk, and not to increased membrane exposure, as evi-
denced by the increased percentage of Gb3 and its correla-
tion with ST MCFI (Fig. 5). This increase in Pk may reflect ei-
ther an increase in Gb3 synthase activity or a decrease in Gb4
synthase activity, as suggested by the Gb3:CDH and Gb3:Gb4
ratios.35,36
Although phenotypic differences in Pk (Gb3) expression
are sufficient to explain increased ST binding to LKE-neg
RBCs, they do not exclude the possibility that LKE-neg RBCs
may also express a LKE-related GSL with Pk-like activity, simi-
lar to that isolated from human platelets (Band 0.03, Table
1).22 In platelets, “antithetical LKE” may serve as an additional
ST receptor in 20 percent of donors and is associated with an
increase in both the percentage of Gb3
and the Gb3:CDH ratio. It was hypoth-
esized that band 0.03 may reflect elevated
Gb3 synthase activity, which successfully
competes with α2-3sialyltransferase for
Gal-Gb4 substrate (SSEA-3, Table 1).
22 El-
evated Gb3 synthase activity, therefore,
would present with both increased Pk and
decreased LKE expression, analogous to
that observed on LKE-neg RBCs. We have
subsequently identified an apparently
novel, ST-binding GSL in the neutral GSL
extracts of LKE-neg RBCs; however, the
quantity is small (<0.5% of total RBC neu-
tral GSL) compared to Gb3. As a conse-
quence, the elevated ST binding to LKE-
neg and LKE-wk+ RBC primarily mirrors
increased Gb3 in these cells.
The inverse relationship between Pk
and LKE may have important clinical im-
plications in the pathophysiology of sev-
eral infectious diseases. LKE was recently
Fig. 5. ST binding to RBCs is directly related to total RBC Gb3.
Gb3 expression by HPTLC (adjusted % total neutral GSL, Table
4) and flow cytometry (ST MCFI) was compared in six donors.
As shown, there was a first-order correlation in which FITC-ST
(MCFI) = 10.2 + percentage of Gb3; R
2 = 0.93.
even LKE-negative donors express small quantities of LKE.
It is likely that only rare persons of the p and Pk phenotypes
are truly negative for LKE (Table 2).8 The high incidence of
LKE in the population, coupled with its relative crypticity on
RBC membranes, may account for the apparent rarity of LKE
alloantibodies.1,3,4,6,34
We also examined Pk or Gb3 expression on RBCs rela-
tive to LKE phenotype. Bruce et al.3 previously observed an
apparent increase in Pk expression on LKE-neg RBCs. How-
Fig. 6. LKE-active glycolipid is present in human RBCs. A) RBC-neutral GSL and kid-
ney ganglioside stained with DPA. B) The total ganglioside fractions from 1 mL of
packed RBCs immunostained with MoAb MC813-70. Lane numbers refer to Donors 1
through 11 (Table 4) and kidney ganglioside control (Lane K). A MoAb MC813-70-
positive RBC glycolipid (Rf 0.01) is identified near the origin in Lanes 6, 7, 10, and 11.
Band 0.04 in Samples 1 through 11 represents nonspecific binding. Numbers on right
refer to mobility Rf of CDH (Rf 0.40), Gb3 (Rf 0.25), Gb4 (Rf 0.16), or MoAb MC813-70-
positive bands (Rfs 0.02 and 0.01). Solvent was C-M-W 65:25:4 (vol/vol).
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identified as the preferred physiologic receptor for P-fim-
bria, a bacterial adhesin expressed by uropathogenic E. coli
strains, which facilitates bacterial colonization of vaginal
epithelium and uroepithelium.12,13 It was recently noted that
the risk of urinary tract infections by P-fimbriated E. coli is
decreased in persons of the secretor phenotype, Le (a–b+).42
It is hypothesized that the expression of LKE is decreased in
the secretor phenotype, because of preferential synthesis of
globo-ABH over LKE on vaginal epithelium and
uroepithelium.12,43 It is possible that LKE may also be de-
pressed on renal epithelial and uroepithelial cells in LKE-neg
and LKE-wk+ persons. If true, a LKE-neg and LKE-wk+ phe-
notype could similarly decrease the risk of infection by
uropathogenic E. coli, much as occurs with the inheritance
of secretor.
In contrast, a LKE-neg and LKE-wk+ phenotype could
potentially increase host susceptibility to infections by S.
dysenteriae and STEC. Both organisms are associated with
infectious diarrhea, hemorrhagic colitis, and HUS, as a re-
sult of the production of ST.17 A 72-kDa multimeric protein,
ST is composed of a ricin-like A subunit and five B subunits,
which mediate toxin binding to Pk (Gb3) on gut mucosa,
endothelium, and other target tissues.17,22 Increased ST
binding and cytotoxicity can be induced in several tissues
by exposure to inflammatory cytokines, which increase syn-
thesis and expression of Pk on cell membranes.18,21 If LKE
and Pk expression on renal epithelial and/or endothelial
cells mimics that observed on RBCs, LKE-neg and LKE-wk+
persons may have an inherited, increased sensitivity to
STEC infections due to constitutively increased Pk expres-
sion on cell membranes. Conversely, increased Pk on RBCs
of LKE-neg and LKE-wk+ persons could potentially de-
crease morbidity from STEC infections by acting as a “sink”
for circulating ST.
In summary, LKE is a high-incidence (>99%) glycolipid
antigen on RBC membranes. The expression of LKE is in-
versely related to Pk expression, with LKE-neg donors ex-
pressing nearly twice the Pk (%Gb3) of LKE-str+ donors. In-
creased Pk expression is associated with increased ST binding
by flow cytometry and HPTLC. Differences in LKE and Pk
expression with LKE phenotype may be associated with dif-
ferences in host susceptibility to S. dysenteriae, STEC, and
uropathogenic E. coli infections.
ACKNOWLEDGMENT
The authors thank Kathy Walker for technical assistance.
REFERENCES
01. Tippett P, Sanger R, Race RR, et al. An agglutinin associ-
ated with the P and the ABO blood group systems. Vox
Sang 1965;10:269-80.
02. Tippett P, Andrews PW, Knowles D, et al. Red cell antigens
P (globoside) and Luke: identification by monoclonal anti-
bodies defining the murine stage-specific embryonic an-
tigens -3 and -4 (SSEA-3 and SSEA-4). Vox Sang
1986;51:53-6.
03. Bruce M, Watt A, Gabra GS, et al. LKE red cell antigen and
its relationship to P1 and P
k: serological study of a large
family. Vox Sang 1988;55:237-40.
04. Moller B, Jorgensen J. Phenotype frequency of LKE in the
Danish population. Hum Hered 1988;38:375-7.
05. Tippett P. Contributions of monoclonal antibodies to un-
derstanding one new and some old blood group systems: In
Garratty G, ed. Red cell antigens and antibodies. Arlington:
American Association of Blood Banks, 1986:83-98.
06. Issitt P, Anstee DJ. Applied blood group serology. 4th ed.
Durham, NC: Montgomery Scientific Publications, 1998.
07. Kannagi R, Cochran NA, Ishigami F, et al. Stage-specific
embryonic antigens (SSEA-3 and -4) are epitopes of a
unique globo-series ganglioside isolated from human tera-
tocarcinoma cells. EMBO J 1983;2:2355-61.
08. Spitalnik PF, Spitalnik SL. The P blood group system: bio-
chemical, serological, and clinical aspects. Transfus Med
Rev 1995;9:110-22.
09. The nomenclature of lipids. International Union of Pure
and Applied Chemistry-International Union of Biology
Commission on Biochemical Nomenclature. J Lipid Res
1978;19:114-28.
10. Gillard BK, Jones MA, Marcus DM. Glycosphingolipids of
human umbilical vein endothelial cells and smooth muscle
cells. Arch Biochem Biophys 1987;256:435-45.
11. Holford LC, Case P, Lawson SN. Substance P,
neurofilament, peripherin and SSEA4 immunocytochemis-
try of human dorsal root ganglion neurons obtained from
post-mortem tissue: a quantitative morphometric analysis.
J Neurocytol 1994;23:577-89.
12. Stapleton AE, Stroud MR, Hakomori SI, Stamm WE. The
globoseries glycosphingolipid sialosyl galactosyl globoside
is found in urinary tract tissues and is a preferred binding
receptor in vitro for uropathogenic Escherichia coli express-
ing pap-encoded adhesins. Infect Immun 1998;66:3856-61.
13. Stroud MR, Stapleton AE, Levery SB. The P histo-blood
group-related glycosphingolipid sialosyl galactosyl
globoside as a preferred binding receptor for
uropathogenic Escherichia coli: isolation and structural
characterization from human kidney. Biochemistry
1998;37:17420-8.
14. Cooling LL, Zhang DS, Koerner TAW. Human platelets ex-
press gangliosides with LKE activity and ABH blood group
activity. Transfusion 2001;41:504-16.
15. Shevinsky LH, Knowles BB, Damjanov I, Solter D. Mono-
clonal antibody to murine embryos defines a stage-specific
embryonic antigen expressed on mouse embryos and hu-
man teratocarcinoma cells. Cell 1982;30:697-705.
16. Fox NW, Damjanov I, Knowles BB, Solter D. Stage-specific
embryonic antigen 3 as a marker of visceral extraembryonic
endoderm. Dev Biol 1984;103:263-6.
Pk AND LUKE ON RBCs
Volume 41, July 2001   TRANSFUSION   907www.transfusion.org
17. O’Brien AD, Holmes RK. Shiga and Shiga-like toxins.
Microbiol Rev 1987;51:206-20.
18. Obrig TG, Louise CB, Lingwood CA, et al. Endothelial het-
erogeneity in Shiga toxin receptors and responses. J Biol
Chem 1993;268:15484-8.
19. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of re-
nal cortical cells in the hemolytic-uremic syndrome: in vivo
and in vitro studies. Infect Immun 1998;66:636-44.
20. Sandvig K, Prydz K, Ryd M, van Deurs B. Endocytosis and
intracellular transport of the glycolipid-binding ligand
Shiga toxin in polarized MDCK cells. J Cell Biol
1991;113:553-62.
21. Van de Kar NA, Monnen LA, Karmali MA, van Hinsbergh
VW. Tumor necrosis factor and interleukin-1 induce ex-
pression of the verocytotoxin receptor
globotriaosylceramide on human endothelial cells: impli-
cations for the pathogenesis of the hemolytic uremic syn-
drome. Blood 1992;80:2755-64.
22. Cooling LL, Walker KE, Gille T, Koerner TA. Shiga toxin
binds human platelets via globotriaosylceramide (Pk anti-
gen) and a novel platelet glycosphingolipid. Infect Immun
1998;66:4355-66.
23. Kannagi R, Levery SB, Ishigami F, et al. New globoseries
glycosphingolipids in human teratocarcinoma reactive
with the monoclonal antibody directed to a developmen-
tally regulated antigen, stage-specific embryonic antigen 3.
J Biol Chem 1983;259:8934-42.
24. Kannagi R, Nudelman E, Levery SB, Hakomori S. A series of
human erythrocyte glycosphingolipids reacting to the
monoclonal antibody directed to a developmentally regu-
lated antigen SSEA-1. J Biol Chem 1982;257:14865-74.
25. Brodin NT, Dahmen J, Nilsson B, et al. Monoclonal anti-
bodies produced by immunization with neoglycoproteins
containing Galα1→4Galβ1→4Glcβ1-O and
Galα1→4Galβ1→4GlcNAcβ-O residues: useful immu-
nochemical and cytochemical reagents for blood group P
antigens and a differentiation marker in Burkitt lymphoma
and other B-cell malignancies. Int J Cancer 1988;42:185-94.
26. Bitzan M, Richardson S, Huang C, et al. Evidence that
verotoxins (Shiga-like toxins) from Escherichia coli bind to
P blood group antigens of human erythrocytes in vitro. In-
fect Immun 1994;62:3337-47.
27. Hakomori SI. Differential reactivities of fetal and adult hu-
man erythrocytes to antisera directed against glycolipids of
human erythrocytes. Vox Sang 1969;16:478-85.
28. Ledeen RW, Yu RK. Gangliosides: structure, isolation and
analysis. In: Ginsberg V, ed. Methods in Enzymology, vol
83. New York: Academic Press, 1982:139-91.
29. Koerner TA, Weinfeld HM, Bullard LS, Williams LC. Anti-
bodies against platelet glycosphingolipids: detection in se-
rum by quantitative HPTLC-autoradiography and asso-
ciation with autoimmune and alloimmune processes.
Blood 1989;74:274-84.
30. Schultz H, Mischer O, Schenk H. [Contents and patterns
of gangliosides in the membranes of human erythro-
cytes] (Engl abstract). Biomed Biochim Acta
1984;43:1127-34.
31. Magnani JL, Smith DF, Ginsburg V. Detection of ganglio-
sides that bind cholera toxin: direct binding of 125I-labeled
toxin to thin-layer chromatograms. Anal Biochem
1980;109:399-402.
32. Buehler J, Macher BA. Glycosphingolipid immunostaining:
detection of antibody binding with an avidin-biotin enzyme
system. Anal Biochem 1986;158:283-7.
33. Bruning FL, Kintz BL. Computational handbook of statis-
tics. Chicago: Harper Collins, 1987.
34. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion
in clinical medicine. 9th ed. Oxford: Blackwell, 1993:188-94.
35. Fletcher KS, Bremer EG, Schwarting GA. P blood group
regulation of glycosphingolipid levels in human erythro-
cytes. J Biol Chem 1979;254:11196-8.
36. Bieberich E, Yu RK. Multi-enzyme kinetic analysis of gly-
colipid biosynthesis. Biochim Biophys Acta 1999;1432:113-
24.
37. Garratty G, Arndt P. Applications of flow cytofluorometry to
transfusion science. Transfusion 1995;35:157-78.
38. Wiels J, Holmes EH, Cochran N, et al. Enzymatic and orga-
nizational difference in expression of a Burkitt lymphoma-
associated antigen (globotriaosylceramide) in Burkitt lym-
phoma and lymphoblastoid cell lines. J Biol Chem
1984;259:14783-7.
39. Kundu SK, Samuelsson BE, Pascher I, Marcus DM. New
gangliosides from human erythrocytes. J Biol Chem
1983;258:13857-66.
40. Levery SB, Salyan ME, Steele SJ, et al. A revised structure for
the disialosyl globo-series gangliosides of human erythro-
cytes and chicken skeletal muscle. Arch Biochem Biophys
1994;312:125-34.
41. Cooling L, Zhang DS, Koerner T. Isolation of Luke antigen
and related, novel gangliosides from human red cells and
kidney (abstract). Transfusion 1999;39(Suppl):91S.
42. Sheinfeld J, Schaeffer AJ, Cordon-Cardo C, et al. Association
of the Lewis blood-group phenotype with recurrent urinary
tract infections in women. N Engl J Med 1989;320:773-7.
43. Stapleton A, Nudelman E, Clausen H, et al. Binding of
uropathogenic Escherichia coli R45 to glycolipids extracted
from vaginal epithelial cells is dependent on histo-blood
group secretor status. J Clin Invest 1992;90:965-72.
